Charles River Laboratories stock (US1591881009): Investor conference appearances and fresh earnings estimate update in focus

Charles River Laboratories shares are drawing attention at the start of June as the United States-based research services group prepares for a series of investor conference appearances and a fresh long-term earnings estimate revision from Zacks Research highlights expectations for multi-year profit growth.

On 06/01/2026, the company announced that management will present at the William Blair 46th Annual Growth Stock Conference on 06/02/2026 at 10:00 a.m. CT (11:00 a.m. ET) and at the Jefferies Global Healthcare Conference on 06/04/2026 at 3:30 p.m. ET, with live webcasts and replays available via its investor relations website, according to a Business Wire release distributed through Morningstar and the company site.

As of late May trading on the New York Stock Exchange, Charles River Laboratories stock, listed under the ticker CRL, changed hands at around USD 181 per share, modestly below its level at the beginning of 2026 when it started the year at about USD 199.62, according to MarketBeat data as of 05/29/2026, and the stock remains part of the U.S. healthcare sector rather than a domestic index heavyweight.

The MarketBeat data for 05/29/2026 indicate that CRL closed the regular session at USD 181.06, down 0.16% on the day, with an after-hours indication of USD 180.77, and this puts the year-to-date performance at approximately minus 9.3% compared to its opening mark on 01/01/2026.

For investors in Germany following the stock via secondary trading, Charles River Laboratories can also be accessed on Tradegate in euros, but liquidity and reference pricing continue to be anchored on the primary New York listing in U.S. dollars.

On the valuation side, a GuruFocus analysis dated 06/01/2026 cites a GF Value of USD 195.41 for Charles River Laboratories compared with a contemporaneous share price of about USD 180.71, implying that the stock was trading roughly 7.5% below that intrinsic value estimate at the time of that assessment, although this is only one methodology among many used by market participants.

In parallel with the conference agenda, Zacks Research published an updated earnings outlook on 06/01/2026 in which its analyst team lifted the forecast for Charles River Laboratories full-year FY2028 earnings per share to USD 13.01 from a previous estimate of USD 12.13, signaling higher modeled profitability expectations over the longer term for the medical research company.

That same Zacks Research report also referenced a UBS Group research note in which the bank increased its target price for CRL shares from USD 170.00 to USD 175.00 and maintained a neutral rating, emphasizing a balanced view on the stock from one major global investment bank while acknowledging the companys role in outsourced drug discovery and development services.

These events underscore how the United States market remains the central arena for sentiment on Charles River Laboratories, with New York Stock Exchange trading, SEC disclosures, and research from banks such as UBS and Zacks Research shaping the narrative around the stock at the beginning of June.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

Charles River Laboratories: core business model

Charles River Laboratories operates as a global outsourced research partner, providing preclinical research models, safety and discovery services, and manufacturing support that enable pharmaceutical and biotechnology clients to progress drug candidates through early development and into clinical trials.

What banks and research houses say about Charles River Laboratories

On the analyst side, the most concrete recent datapoints center on the combination of Zacks Research modeling and a UBS Group price target change disclosed in coverage of Charles River Laboratories at the start of June, adding to the picture formed by broader Wall Street consensus data.

According to a 06/01/2026 note summarized by MarketBeat and Zacks, the Zacks Research team now projects FY2028 earnings per share of USD 13.01 for Charles River Laboratories, up from a previous estimate of USD 12.13 for that year, reflecting higher expectations for the companys long-term earnings power in its role as a medical research and contract laboratory specialist.

In the same context, UBS Group raised its target price for CRL stock to USD 175.00 from USD 170.00 and reiterated a neutral stance in its rating, indicating that the bank sees modest incremental upside in its valuation framework while still positioning the shares as fairly balanced in terms of risk and reward compared with the current trading range.

Other aggregators such as MarketBeat compile a wider set of recommendations and average price targets from multiple brokers, but the UBS and Zacks datapoints provide specific, dated figures that are particularly relevant for investors examining the stock around the time of the June investor conferences.

Conclusion

The combination of upcoming presentations at the William Blair and Jefferies conferences and the upward revision to long-dated EPS estimates from Zacks Research keeps Charles River Laboratories firmly in view for investors tracking the U.S. healthcare and contract research space.

While the shares trade below their level at the start of 2026 and somewhat under one valuation models GF Value estimate, the updated UBS target and Zacks projections provide fresh reference points for how the market is calibrating expectations for the companys earnings trajectory.

How the stock reacts around the June conference discussions, together with any additional guidance or commentary from management, will help determine whether current pricing on the New York Stock Exchange continues to reflect a cautious stance or begins to incorporate a more constructive outlook on growth and margins.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.